Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesScancell Holdings plc

Scancell Holdings plc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-06T21:46:51.551198Z
Market Cap
191.29M

Momentum Score

…

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.12
Low
0.33
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Scancell Holdings plc is a clinical-stage biotechnology company developing T-cell focused cancer immunotherapies using its ImmunoBody and Moditope platforms. Long-term growth may be driven by clinical trial progress, successful combinations with checkpoint inhibitors, and licensing or partnership deals to advance and commercialize candidates. Investors may find exposure to differentiated antigen-targeting approaches and potential for durable anti-tumor immune responses attractive.

Key risks include high clinical and regulatory failure risk, limited revenues and cash reserves requiring fundraising, execution challenges scaling manufacturing and development, and intense competition in immuno-oncology.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.15
Dividend Yield
-
Revenue TTM
4.71M
Revenue Per Share
0.01
Gross Profit TTM
4.47M
Debt / Equity
-4.24
ROE
-269.84%
Net Debt
-0.63M
ROCE
404.12%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Income before tax -15.30M -14.30M -14.30M -3.77M -16.80M
Net income -12.27M -11.94M -11.94M -2.06M -15.48M
Selling general administrative 4.79M 5.02M 5.02M 4.79M 3.35M
Gross profit 4.47M 4.75M 4.75M - -
Reconciled depreciation 0.88M 0.97M 0.90M 0.74M 0.25M
Ebit -15.00M -13.09M - -8.05M -15.15M
Ebitda -14.51M -12.19M - -7.31M -14.90M
Depreciation and amortization 0.49M 0.90M - 0.74M 0.25M
Operating income -15.00M -11.92M -11.92M -13.30M -8.83M
Other operating expenses 19.71M 17.19M - 13.30M 8.83M
Interest expense 1.38M 1.09M 1.22M 2.88M 1.65M
Tax provision -3.03M -3.26M -2.37M -1.70M -1.33M
Interest income 0.34M 0.35M 0.28M 0.00M 0.00M
Net interest income -1.38M -0.73M -0.93M 2.37M -7.97M
Income tax expense 3.03M -2.37M - -1.70M -1.33M
Total revenue 4.71M 5.27M 5.27M 0.00M 0.00M
Total operating expenses 19.47M 16.67M 17.19M 13.30M 8.83M
Cost of revenue 0.24M 0.53M 0.53M - -
Total other income expense net -0.30M -2.38M - 9.53M -7.97M
Net income from continuing ops -12.27M -5.86M -11.94M -2.06M -15.48M
Net income applicable to common shares - - - -2.06M -15.48M
Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Total assets 23.09M 23.58M 30.27M 38.52M 49.06M
Intangible assets 1.62M - - - -
Other current assets 3.73M 1.20M - - -
Total liab 26.93M 27.08M 36.50M 20.41M 29.57M
Total stockholder equity -3.83M -3.50M -6.23M 18.11M 19.48M
Other current liab 10.05M 2.72M - 0.34M 0.06M
Common stock 1.04M 0.93M - 0.81M 0.81M
Capital stock 1.04M 0.93M 0.82M 0.81M 0.81M
Retained earnings -91.42M -84.19M -74.36M -49.12M -47.05M
Other liab - - - 10.10M 12.03M
Good will - - 3.42M 3.42M 3.42M
Cash 16.89M 14.82M 19.92M 28.73M 41.11M
Total current liabilities 26.80M 6.39M 3.28M 2.45M 2.29M
Net debt -0.63M 5.05M - -20.55M -25.66M
Short term debt 16.14M 2.03M - 0.32M 0.21M
Short long term debt 15.75M 1.61M - - -
Short long term debt total 16.27M 19.87M - 8.18M 15.46M
Other stockholder equity 82.40M 79.75M - 66.41M 65.72M
Property plant equipment - - - 2.74M 0.97M
Total current assets 20.62M 21.87M 24.61M 32.36M 44.67M
Net tangible assets - - - 14.70M 16.07M
Net receivables 3.18M 5.85M 0.54M 3.19M 2.84M
Long term debt 0.00M 17.37M 18.48M 7.01M 15.18M
Accounts payable 0.61M 1.46M 2.97M 2.14M 2.09M
Accumulated other comprehensive income 4.14M 3.48M - - -
Non current assets total 2.47M 1.71M 5.66M 6.16M 4.39M
Capital lease obligations 0.51M 0.89M 1.05M 1.17M 0.27M
Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Investments -1.20M 0.18M 0.08M -1.26M -0.74M
Change to liabilities - - - 0.05M 1.05M
Total cashflows from investing activities -1.20M 0.18M - -1.26M -0.74M
Net borrowings -0.45M 0.00M - -0.39M 23.35M
Total cash from financing activities 9.69M 10.39M - -0.93M 46.08M
Net income -12.27M -9.12M -11.94M -3.77M -16.80M
Change in cash 2.08M -5.10M -8.80M -12.38M 37.53M
Begin period cash flow 14.82M 19.92M 28.73M 41.11M 3.58M
End period cash flow 16.89M 14.82M 19.92M 28.73M 41.11M
Total cash from operating activities -6.40M -15.66M -8.14M -10.19M -7.80M
Issuance of capital stock 11.28M 11.99M 0.17M 0.00M 24.14M
Depreciation 0.88M 0.97M 0.90M 0.74M 0.25M
Other cashflows from investing activities -1.19M 0.35M - 0.00M 0.00M
Change to account receivables 0.75M -0.84M - 0.32M -0.60M
Other cashflows from financing activities 10.54M -1.24M - -1.26M 21.94M
Change to netincome - - - -9.24M 6.98M
Capital expenditures 0.01M 0.18M 0.20M 1.27M 0.74M
Change in working capital 0.75M -0.71M 0.94M 0.37M 0.45M
Stock based compensation 1.36M 0.66M 0.73M 0.69M 0.33M
Other non cash items 2.89M -7.46M 2.38M -8.23M 7.97M
Free cash flow -6.41M -15.84M -8.34M -11.46M -8.55M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Scancell Holdings plc

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Bellhouse Building, Oxford, United Kingdom, OX4 4GD

44 18 6558 2066

https://www.scancell.co.uk

60

Name Title Year Born
Prof. Lindy Gillian Durrant Ph.D. Founder, CEO, Chief Scientific Officer & Director NA
Dr. Sally Elizabeth Adams Chief Devel. Officer & Director 1961
Mr. Keith Green Director of Fin. & Admin. and Company Sec. NA
Dr. Samantha Paston Ph.D. Head of Translational Research NA
Dr. Adrian Parry Ph.D. Head of Manufacturing NA
Ms. Akua Asare Head of Quality NA
Mr. Fayaz Master Head of Clinical Operations NA
Dr. Phillip John L'Huillier MBA, Ph.D. CEO & Director 1962
Prof. Lindy Gillian Durrant Ph.D. Chief Scientific Officer, Director & Founder 1957
Mr. David Schilansky Interim Chief Financial Officer 1975

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…